Integra LifeSciences Holdings (IART) Earnings Date & Reports

Key Takeaways

• Fourth-quarter revenue was $434.9 million, down 1.7% year over year and slightly ahead of analyst consensus.
• Adjusted EPS (earnings per share) came in at $0.83, beating estimates but falling 14.4% from the prior-year quarter.
• The company reported a GAAP (generally accepted accounting principles) net loss of $1.7 million, or $0.02 per share.
• Codman Specialty Surgical grew 2.7%, while Tissue Technologies revenue declined 12.8%, driven by weakness in wound reconstruction.
• Full-year 2026 guidance calls for revenue of $1.66 billion to $1.70 billion and adjusted EPS of $2.30 to $2.40.

Earnings Context and Why It Matters

Integra LifeSciences (IART) closed out a difficult 2025 with fourth-quarter results that highlighted both progress and persistent pressure. The medical technology company has been navigating quality remediation efforts, supply constraints, and tariff headwinds, even as demand across much of its surgical portfolio remains solid. For investors, this report matters because it offers a clearer read on whether Integra is moving past its operational challenges, and because management's 2026 guidance sets the bar for a potential recovery. The sharp divergence between its two business segments — one growing and one shrinking — frames the key question heading into the new year.

Reported Results

Integra reported fourth-quarter 2025 revenue of $434.9 million, a decline of 1.7% on a reported basis and 2.5% on an organic basis compared with the prior-year period. The top line edged past the Zacks Consensus Estimate of roughly $434 million. Adjusted EPS came in at $0.83, exceeding consensus expectations of about $0.79 to $0.80, though the figure was down from $0.97 a year earlier. On a GAAP basis, the company posted a net loss of $1.7 million, or $0.02 per share, compared with a profit of $0.25 per share in the year-ago quarter.

Segment results told a divergent story. Codman Specialty Surgical revenue rose 2.7% to $323.3 million, supported by strength in neurosurgery, instruments, and ENT (ear, nose, and throat) products. Tissue Technologies revenue fell 12.8% to $111.6 million, with wound reconstruction down 21.4% on an organic basis due to remediation work on MediHoney and a tough comparison against a record prior-year quarter for Integra Skin. Private label sales rose 20.1%.

For the full year, revenue was $1.635 billion, up 1.5% on a reported basis, while adjusted EPS was $2.23, down 12.9% from 2024. Adjusted gross margin in the fourth quarter was 61.7%, down 350 basis points year over year, reflecting tariffs, compliance costs, and an unfavorable product mix.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking companies like Integra LifeSciences across the medical technology space, it offers a faster way to surface relevant opportunities.

Market Reaction and Investor Sentiment

Shares of Integra LifeSciences moved modestly higher following the report, rising around 0.4% after the announcement and roughly 3.5% in pre-market trading. The relatively muted reaction reflects a market weighing two opposing signals: a top-line and adjusted-EPS beat against a year-over-year earnings decline, continued margin compression, and a still-weak Tissue Technologies segment. Sentiment remains cautious given that the stock has traded near 52-week lows after a difficult year, and investors appear focused more on the trajectory of 2026 guidance than on the quarter's headline beat.

Forward Outlook and Key Factors to Monitor

Management's guidance is the central reference point for the year ahead. For full-year 2026, Integra expects revenue of $1.66 billion to $1.70 billion, implying reported growth of 1.6% to 4.1%, and adjusted EPS of $2.30 to $2.40. First-quarter 2026 guidance calls for revenue of $375 million to $390 million and adjusted EPS of $0.37 to $0.45.

Several factors will shape whether Integra can meet those targets. Supply reliability and the completion of its quality remediation work remain the primary drivers of performance predictability. Investors should watch for progress on the Braintree manufacturing facility and the planned return of SurgiMend to the market in the fourth quarter of 2026, as well as ongoing EU MDR (European Union Medical Device Regulation) compliance spending.

Margin recovery is another key watch item. Tariffs and compliance costs pressured gross margin throughout 2025, and management's guidance reflects tariff assumptions made before a recent Supreme Court ruling on Section 122 tariffs. Cost management and a rebound in wound reconstruction will be essential to stabilizing profitability.

Finally, free cash flow is expected to improve as heavy infrastructure investments wind down, a development that could support deleveraging. With net debt around $1.6 billion and a leverage ratio near 4.5x, any progress on cash generation will be closely scrutinized.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations